Literature DB >> 3065113

Low acute insulin response to intravenous glucose. A sensitive but non-specific marker of early stages of type 1 (insulin-dependent) diabetes.

B Vialettes1, C Mattei-Zevaco, C Badier, G Ramahandridona, V Lassmann-Vague, P Vague.   

Abstract

Preventive treatment of Type 1 (insulin-dependent) diabetes presupposes early and accurate diagnosis of prediabetic states. The low acute insulin response to intravenous glucose has been proposed as a marker of both pre-Type 1 and pre-Type 2 (non-insulin-dependent) diabetes. In order to test the reliability of this marker for clinical detection of Type 1 diabetes we looked for this anomaly in 150 first degree relatives of Type 1 diabetic patients, 31 relatives of Type 2 diabetic patients and 39 young non-obese diabetic patients with mild or transient hyperglycaemia. The low acute insulin response was defined by a peak insulin value (sum of plasma insulin at 2 and 5 min after glucose load, 0.3 g/kg body weight) below 50 microU/ml. It was observed in 12% of the relatives of Type 1 diabetic patients (2 of them became diabetic) and in 13% of the relatives of Type 2 diabetic patients. Reproducibility of the peak insulin value in 2 subsequent tests (r = 0.749) was inadequate to interpret small variations in one individual. In the population of 39 diabetic patients, 10 subsequently developed typical Type 1 diabetes, 9 were low insulin responders. In the 29 patients who are still non-insulin-dependent 3 years later, the anomaly was found in the 3 islet cell antibody-positive subjects and 11 out of 26 patients with no detectable antibodies. In conclusion, low acute insulin response to glucose is a sensitive but non-specific marker of early stages of Type 1 diabetes as this anomaly is shared by both Type 2 and Type 1 diabetes.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3065113     DOI: 10.1007/bf00264765

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  16 in total

1.  Insulin response to glucose and tolbutamide in "essential" versus "pancreatic" mild glucose intolerance.

Authors:  P Vague; G Ramahandridona; A Gerolami
Journal:  Diabetes       Date:  1974-11       Impact factor: 9.461

2.  Early insulin responses to glucose and to tolbutamide in maturity-onset diabetes.

Authors:  N Varsano-Aharon; E Echemendia; R S Yalow; S A Berson
Journal:  Metabolism       Date:  1970-06       Impact factor: 8.694

3.  Quantitative and qualitative changes in the early insulin response to glucose in subjects with impaired carbohydrate tolerance.

Authors:  K P Ratzmann; B Schulz; P Heinke; D Michaelis
Journal:  Diabetes Care       Date:  1981 Jan-Feb       Impact factor: 19.112

4.  [Proportion of low insulin responders to glucose among the offspring of maturity-onset diabetics (author's transl)].

Authors:  P Vague; G Ramahandridona; J Vague
Journal:  Diabete Metab       Date:  1975-03

5.  Triad of markers for identifying children at high risk of developing insulin-dependent diabetes mellitus.

Authors:  F Ginsberg-Fellner; M E Witt; B H Franklin; S Yagihashi; Y Toguchi; M J Dobersen; P Rubinstein; A L Notkins
Journal:  JAMA       Date:  1985-09-20       Impact factor: 56.272

6.  First-degree relatives of patients with type I diabetes mellitus. Islet-cell antibodies and abnormal insulin secretion.

Authors:  S Srikanta; O P Ganda; A Rabizadeh; J S Soeldner; G S Eisenbarth
Journal:  N Engl J Med       Date:  1985-08-22       Impact factor: 91.245

7.  The development of insulin-dependent diabetes mellitus among relatives.

Authors:  T J Orchard; A L Rosenbloom
Journal:  Diabetes Care       Date:  1985 Sep-Oct       Impact factor: 19.112

8.  Pre-type I diabetes. Linear loss of beta cell response to intravenous glucose.

Authors:  S Srikanta; O P Ganda; R E Gleason; R A Jackson; J S Soeldner; G S Eisenbarth
Journal:  Diabetes       Date:  1984-08       Impact factor: 9.461

9.  Evidence for a long prediabetic period in type I (insulin-dependent) diabetes mellitus.

Authors:  A N Gorsuch; K M Spencer; J Lister; J M McNally; B M Dean; G F Bottazzo; A G Cudworth
Journal:  Lancet       Date:  1981 Dec 19-26       Impact factor: 79.321

10.  [Comparison of various types of islet cell antibodies in diabetes as a function of its cause and duration].

Authors:  B Vialettes; C Di Campo-Rougerie; V Lassmann; P Vague
Journal:  Presse Med       Date:  1983-10-22       Impact factor: 1.228

View more
  6 in total

1.  Is a low insulin response to intravenous glucose a marker of type 1 (insulin-dependent) insulin?

Authors:  P P Razenberg
Journal:  Diabetologia       Date:  1989-02       Impact factor: 10.122

2.  Autoimmune polyendocrine failure--type 1 (insulin-dependent) diabetes mellitus and hypothyroidism--after allogeneic bone marrow transplantation in a patient with lymphoblastic leukaemia.

Authors:  B Vialettes; D Maraninchi; M P San Marco; F Birg; A M Stoppa; C Mattei-Zevaco; C Thivolet; L Hermitte; P Vague; P Mercier
Journal:  Diabetologia       Date:  1993-06       Impact factor: 10.122

3.  Acute insulin response to intravenous glucose, glucagon and arginine in some subjects at risk for type 1 (insulin-dependent) diabetes mellitus.

Authors:  S Bardet; V Rohmer; D Maugendre; M Marre; G Semana; J M Limal; H Allannic; B Charbonnel; P Saï
Journal:  Diabetologia       Date:  1991-09       Impact factor: 10.122

4.  β Cell dysfunction exists more than 5 years before type 1 diabetes diagnosis.

Authors:  Carmella Evans-Molina; Emily K Sims; Linda A DiMeglio; Heba M Ismail; Andrea K Steck; Jerry P Palmer; Jeffrey P Krischer; Susan Geyer; Ping Xu; Jay M Sosenko
Journal:  JCI Insight       Date:  2018-08-09

5.  Reduced β-cell function in early preclinical type 1 diabetes.

Authors:  Maarit K Koskinen; Olli Helminen; Jaakko Matomäki; Susanna Aspholm; Juha Mykkänen; Marjaana Mäkinen; Ville Simell; Mari Vähä-Mäkilä; Tuula Simell; Jorma Ilonen; Mikael Knip; Riitta Veijola; Jorma Toppari; Olli Simell
Journal:  Eur J Endocrinol       Date:  2015-11-30       Impact factor: 6.664

Review 6.  Cause or effect? A review of clinical data demonstrating beta cell dysfunction prior to the clinical onset of type 1 diabetes.

Authors:  Emily K Sims; Linda A DiMeglio
Journal:  Mol Metab       Date:  2019-09       Impact factor: 7.422

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.